Lumos Pharma is a biotechnology business based in the US. Lumos Pharma shares (LUMO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.34 – the same closing value as a week prior. Lumos Pharma employs 30 staff and has a trailing 12-month revenue of around $2.2 million.
Offer ends 4/1/25. Customer must fund their Active invest account with at least $50 within 30 days of opening the account. Probability of customer receiving $2,000 is 0.028%. See full terms and conditions at https://www.sofi.com/greenintwoterms/.
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – LUMO.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Lumos Pharma stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Lumos Pharma stock price (NASDAQ: LUMO)
Use our graph to track the performance of LUMO stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Lumos Pharma price performance over time
Historical closes compared with the close of $4.34 from 2024-12-11
1 week (2025-03-12)
N/A
1 month (2025-02-19)
N/A
3 months (2024-12-19)
N/A
6 months (2024-09-23)
15.43%
1 year (2024-03-22)
56.12%
2 years (2023-03-23)
30.72%
3 years (2022-03-23)
9.85
5 years (2020-03-23)
7.55
Lumos Pharma financials
Revenue TTM
$2.2 million
Gross profit TTM
$1.5 million
Return on assets TTM
-69.64%
Return on equity TTM
-172.83%
Profit margin
0%
Book value
$0.57
Market Capitalization
$37.5 million
TTM: trailing 12 months
Lumos Pharma share dividends
We're not expecting Lumos Pharma to pay a dividend over the next 12 months.
Have Lumos Pharma's shares ever split?
Lumos Pharma's shares were
split on a 1:9 basis on 18 March 2020
. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lumos Pharma shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Lumos Pharma shares which in turn could have impacted Lumos Pharma's share price.
Lumos Pharma share price volatility
Over the last 12 months, Lumos Pharma's shares have ranged in value from as little as $1.3701 up to $4.5756. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lumos Pharma's is 0.331. This would suggest that Lumos Pharma's shares are less volatile than average (for this exchange).
Lumos Pharma overview
Lumos Pharma, Inc. , a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas. As of December 12, 2024, Lumos Pharma, Inc.
Frequently asked questions
What percentage of Lumos Pharma is owned by insiders or institutions? Currently 32.694% of Lumos Pharma shares are held by insiders and 24.271% by institutions.How many people work for Lumos Pharma? Latest data suggests 30 work at Lumos Pharma.When does the fiscal year end for Lumos Pharma? Lumos Pharma's fiscal year ends in December.Where is Lumos Pharma based? Lumos Pharma's address is: 4200 Marathon Boulevard, Austin, TX, United States, 78756What is Lumos Pharma's ISIN number? Lumos Pharma's international securities identification number is: US55028X1090What is Lumos Pharma's CUSIP number? Lumos Pharma's Committee on Uniform Securities Identification Procedures number is: 55028X109
A deep dive into the highlights and limitations of Robinhood.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
